9 research outputs found

    Usos populars de les plantes i gestió del paisatge: alguns resultats d'una recerca etnobotànica a l'Alt Empordà.

    Get PDF
    Des dels temps més reculats, les societats humanes han fet una utilització i una gestió de la natura per a treure'n profit en aspectes diversos de la vida, entre els quals l'alimentari i el medicinal han jugat papers preponderants, però no han pas estat, ni de bon tros, els únics. En aquest treball exposarem els resultats d'enquestes etnobotàniques realitzades en els darrers anys a gairebé dos centenars d'informants de la comarca, tot comentant particularment les qüestions més relacionades amb les plantes que configuren el paisatge i llurs usos populars més vinculats amb la llar i la vida rurals

    Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19 : a multicentre, randomised, double-blind, non-inferiority phase IIb trial

    Get PDF
    A SARS-CoV-2 protein-based heterodimer vaccine, PHH-1V, has been shown to be safe and well-tolerated in healthy young adults in a first-in-human, Phase I/IIa study dose-escalation trial. Here, we report the interim results of the Phase IIb HH-2, where the immunogenicity and safety of a heterologous booster with PHH-1V is assessed versus a homologous booster with BNT162b2 at 14, 28 and 98 days after vaccine administration. The HH-2 study is an ongoing multicentre, randomised, active-controlled, double-blind, non-inferiority Phase IIb trial, where participants 18 years or older who had received two doses of BNT162b2 were randomly assigned in a 2:1 ratio to receive a booster dose of vaccine-either heterologous (PHH-1V group) or homologous (BNT162b2 group)-in 10 centres in Spain. Eligible subjects were allocated to treatment stratified by age group (18-64 versus ≥65 years) with approximately 10% of the sample enrolled in the older age group. The primary endpoints were humoral immunogenicity measured by changes in levels of neutralizing antibodies (PBNA) against the ancestral Wuhan-Hu-1 strain after the PHH-1V or the BNT162b2 boost, and the safety and tolerability of PHH-1V as a boost. The secondary endpoints were to compare changes in levels of neutralizing antibodies against different variants of SARS-CoV-2 and the T-cell responses towards the SARS-CoV-2 spike glycoprotein peptides. The exploratory endpoint was to assess the number of subjects with SARS-CoV-2 infections ≥14 days after PHH-1V booster. This study is ongoing and is registered with , . From 15 November 2021, 782 adults were randomly assigned to PHH-1V (n = 522) or BNT162b2 (n = 260) boost vaccine groups. The geometric mean titre (GMT) ratio of neutralizing antibodies on days 14, 28 and 98, shown as BNT162b2 active control versus PHH-1V, was, respectively, 1.68 (p < 0.0001), 1.31 (p = 0.0007) and 0.86 (p = 0.40) for the ancestral Wuhan-Hu-1 strain; 0.62 (p < 0.0001), 0.65 (p < 0.0001) and 0.56 (p = 0.003) for the Beta variant; 1.01 (p = 0.92), 0.88 (p = 0.11) and 0.52 (p = 0.0003) for the Delta variant; and 0.59 (p ≤ 0.0001), 0.66 (p < 0.0001) and 0.57 (p = 0.0028) for the Omicron BA.1 variant. Additionally, PHH-1V as a booster dose induced a significant increase of CD4 + and CD8 + T-cells expressing IFN-γ on day 14. There were 458 participants who experienced at least one adverse event (89.3%) in the PHH-1V and 238 (94.4%) in the BNT162b2 group. The most frequent adverse events were injection site pain (79.7% and 89.3%), fatigue (27.5% and 42.1%) and headache (31.2 and 40.1%) for the PHH-1V and the BNT162b2 groups, respectively. A total of 52 COVID-19 cases occurred from day 14 post-vaccination (10.14%) for the PHH-1V group and 30 (11.90%) for the BNT162b2 group (p = 0.45), and none of the subjects developed severe COVID-19. Our interim results from the Phase IIb HH-2 trial show that PHH-1V as a heterologous booster vaccine, when compared to BNT162b2, although it does not reach a non-inferior neutralizing antibody response against the Wuhan-Hu-1 strain at days 14 and 28 after vaccination, it does so at day 98. PHH-1V as a heterologous booster elicits a superior neutralizing antibody response against the previous circulating Beta and the currently circulating Omicron BA.1 SARS-CoV-2 variants in all time points assessed, and for the Delta variant on day 98 as well. Moreover, the PHH-1V boost also induces a strong and balanced T-cell response. Concerning the safety profile, subjects in the PHH-1V group report significantly fewer adverse events than those in the BNT162b2 group, most of mild intensity, and both vaccine groups present comparable COVID-19 breakthrough cases, none of them severe. HIPRA SCIENTIFIC, S.L.U

    Las plantas medicinales en el inventario español sobre los conocimientos Tradicionales relativos al patrimonio natural y a la biodiversidad

    No full text
    En las últimas décadas las organizaciones internacionales han puesto de manifiesto la importancia de los conocimientos ecológicos tradicionales para la conservación y el uso sostenible de la diversidad biológica, como se refleja en el Convenio sobre la Diversidad Biológica (CBD 1992). En España, el marco jurídico que recoge las normas y recomendaciones de esta estrategia es la Ley de Patrimonio Natural y Biodiveresidad 42/2007 que establece la creación del Inventario Español de Conocimientos Tradicionales (IECT) relevantes para la conservación y el uso sostenible de la biodiversidad y geodiversidad. Desde hace más de un año un equipo de más de 60 investigadores, incluyendo botánicos, zoólogos, antropólogos, ecólogos y geólogos de más de 20 centros de investigación y universidades del estado español, están trabajando en el IEDT, con el objetivo de recopilar y difundir la información publicada sobre los conocimientos tradicionales relativos a la flora, fauna, geodiversidad y el manejo de los ecosistemas

    Sharing Plant Uses with Animals: Plants Used for Feeding and Curing Humans and Animals in the Spanish Inventory of Traditional Knowledge Related to Biodiversity

    No full text
    Trabajo presentado en la 57th Annual Meeting of the Society for Economic Botany (Cultural resilience and resource extraction: preserving plants & people of degraded ecosystems), celebrada en Pine Mountain (USA) del 5 al 9 de junio de 2016.Spain has a very rich and dynamic traditional ecological knowledge system that has suffered severe erosion over the last decades. This knowledge has been deeply influenced by a rich and diverse historical heritage that includes many centuries old documents from ancient cultures, some over 2000 years old. Spanish acute useful flora comprises around 3,000 species, most of them autochthonous. A team of more than 70 scientists from more than 30 universities and other research centres are developing the Spanish Inventory of Traditional Knowledge. The inventory includes a database with information from over180 papers. The review of such papers showed that more than 2,300 plant species are used in human and animal food and medicine: 1,681 in human medicine, 1,295 in animal food, 953 in human food and 709 in veterinary medicine. Nearly 14% of the species (313) are shared in the four categories and a very important amount of species are used both for humans and animals: 35% of the species (800) are employed in animal food and medicine, 31% (710) in human food and medicine, 28% (650) in human and veterinary medicine and 27% (624) in animal and human food. This high percentage of overlap between human and animal uses may indicate that the observation of animal behaviour , specially feeding and selfmedication behaviours, might have given clues to humans on how to use food and medicinal plants[Lo1]. It also reinforces the idea that food and medicine represent a continuum not only for humans, but also for animals.Peer reviewe

    Sustainability of traditional ecological knowledge: importance, distribution, endemicity and conservation of Spanish medicinal plants

    No full text
    Trabajo presentado en la 58th Annual Meeting of the Society for Economic Botany (Living in a global world: local knowledge ans sustainability), celebrada en Braganza (Portugal) del 4 al 9 de junio de 2017.-- IECTB authors: L Aceituno, R Acosta, A Alvarez, E Barroso, J Blanco, MA Bonet, L Calvet, E Carrio, R Cavero, U DAmbrosio , L Delgado, J Fajardo, I Fernandez-Ordonez, J Garcia, T Garnatje, JA Gonzalez, R Gonzalez-Tejero, A Gras, E Hernandez-Bermejo, E Laguna, JA Latorre, C. Lopez, MJ Macia, E Marcos, V Martinez, G Menendez, M Molina, R Morales, LM Munoz, C Obon, R Ontillera, M Parada, A Perdomo, I Perez, MP Puchades, V Reyes-Garcia, M Rigat, S Rios, D Rivera, R Rodriguez, O Rodriguez, R Roldan, L San Joaquin, FJ Tardio, JR Vallejo, J Valles, H Velasco and A Verde.More than 17,000 of the plant species of the world have been used as medicines. The Mediterranean basin, and specifically Spain, has a great floristic and ethnobotanical richness, comprising its useful flora around 3,000 plant species. This paper studies medicinal plants traditionally used in Spain in order to analyze the sustainability of their exploitation. Given that sustainability is related to the amount of the resource and its gathering pressure, its availability and cultural importance were analysed based on: the number of papers cited from a selection of over 180 papers, the number of 10x10 km UTM grid cells in which the plants were represented, the number of phytosociological inventories in which the presence of the plant has been registered, and searched on their current conservation status in European, national and regional legislations. The total number of wild or naturalized medicinal species in Spain reaches 1,393, 15% of them being endemic. A positive correlation was found among cultural importance and abundance (ρ=0.48) and among cultural importance and distribution (ρ=0.502), showing that abundant widely distributed species are those more commonly used. Most of the medicinal plants (72%) do not appear on the consulted regulations and do not have any legal protection or known threat and only 11 species are registered in any of the annexes of the European Habitats directive. While this study confirms that people tend to select as medicinal abundant and widely distributed species, many other criteria are used for selecting them.Peer reviewe
    corecore